The FDA has cleared IntelligentMDx to market its molecular assay for use in detecting multiple strains of influenza A and B as well as respiratory syncytial virus. The IMDx Flu A/B and RSV test, which runs on Abbott's automated m2000 diagnostic platform, can simultaneously generate results for as many as 94 patient specimens, the company said.

Related Summaries